PTC Therapeutics, Inc.
100 Corporate Court
534 articles with PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 "Don Clifton Strengths-Based Culture Award" from Gallup.
PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi™ (risdiplam) in the European Union under its License and Collaboration Agreement with Roche.
PTC Therapeutics Announces the European Approval of Evrysdi™ for the Treatment of Spinal Muscular Atrophy
PTC Therapeutics, Inc. announced that the European Commission has granted marketing authorization to Evrysdi™ for the treatment of spinal muscular atrophy in patients 2 months and older.
Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients
Patients and caregivers reported a greater ability to complete activities of daily livingwith increased independence
PTC Presents Results from a Real-World Study of Steroid Switching in the Treatment of Patients with Dystrophinopathies
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from a real-world study of patients with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) who switched from prednisone to EMFLAZA® (deflazacort) following the FDA approval.
CHMP Adopts Positive Opinion for Evrysdi™ for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and Older
PTC Therapeutics, Inc., announced that the European Medicines Agency Committee for Medicinal Products for Human Use has recommended the approval of Evrysdi™ for the treatment of 5q spinal muscular atrophy in patients 2 months and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 with one to four SMN2 copies.
PTC Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced financial results for the fourth quarter and full year ending December 31, 2020 and provided a corporate update.
Positive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The New England Journal of Medicine
PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the publication of results from the dose finding Part 1 of the pivotal FIREFISH study evaluating Evrysdi™ (risdiplam) in infants with symptomatic type 1 spinal muscular atrophy (SMA) in The New England Journal of Medicine (NEJM).
PTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19
-- PTC299 is an oral therapy that has a novel dual mechanism of action that inhibits viral replication and attenuates the uncontrolled inflammatory response -- -- Stage 1 of the clinical trial is complete --
PTC Therapeutics, Inc. announced that management will present a company overview at the following conferences
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year-end 2020 financial results and provide an update on the company's business and outlook on Thursday, February 25, 2021 at 4:30 p.m. (ET) after the closing of the market.
It was a busy week for clinical trial updates. Here’s a look.
PTC Therapeutics to Host Call to Review Results from its Study of Translarna™ (ataluren) in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call today at 5:30 p.m. E.T. to review results from its clinical study 045 of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy.
PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category
- New category targets programs that support the transition from adolescence to adulthood - - Proposal submissions for 2021 STRIVE Awards are due March 15, 2021 -
PTC Therapeutics, Inc. announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate of 13,465 shares of its common stock and 4,665 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 10 new employees.
PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference
PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its R&D pipeline and commercial progress at the 39th Annual J.P. Morgan Healthcare Conference today, Monday, Jan. 11 at 7:30 a.m. EST.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11 th at 7:30 a.m. EST . The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC The
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing Translarna on Tuesday, December 15 at 12:00 noon ET . The Translarna Deep Dive will provide an overview of results from the clinical and real-world data generated to date for the treatment of nonsense mutation Duchenne muscula
It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.